药明合联（02268）今日盘中大涨8%，股价表现强劲。这一涨幅主要受到公司发布的2024年度财报及分析师积极评级的推动。
根据公司最新发布的财报显示，药明合联2024年度录得纯利10.7亿元人民币，同比大幅增长277.2%，每股盈利89分。期内收益达40.52亿元，按年增加90.8%；毛利为12.4亿元，上升121.6%。这些数据凸显了公司在过去一年中的强劲业绩表现。
多家大型投资银行对药明合联的前景持乐观态度。花旗给予"买入"评级，并将目标价从43港元上调至46港元。摩根大通维持"增持"评级，同样将目标价上调至46港元。分析师们普遍认为公司2025财年的销售增长预期可能过于保守，并上调了未来几年的销售预测。这些积极的分析评级进一步推动了投资者对公司未来发展的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.